Biomimetic Ligands: A cost effective alternative to biological ligands, allowing rapid development of an Affinity Chromatography capture step.
The Biopharmaceutical Industry faces the challenge of maintaining product safety (purity) whilst under pressure to get to market quicker and reduce overall processing cost. The use of Affinity Chromatography can provide a high level of purity but often at an increased cost due to the need of high purity biological ligands, such as Protein A.
The use of Mimetic Ligands™ can often overcome the costs of biological ligands and allow much more effective cleaning regimes thereby increasing resin life and reducing costs further.
During this webinar we will outline the advantages of utilizing Affinity Chromatography as an initial capture step.
You will learn how computational chemistry can be used to rapidly identify potential affinity ligands and how these ligands can then be synthesised and coupled to a chromatography matrix, to produce an extremely effective affinity adsorbent.
Examples showing the development of Mimetic Ligands™ for the purification of albumin fusion proteins and transferrin fusion proteins will be given to highlight successful implementation programmes.
If you are looking to develop purification processes for complex separations or wish to learn about the latest ligand screening technologies then please sign up for this webinar.
Presented by
Dr Steve Burton,
CEO, ProMetic BioSciences Ltd
Dr Burton was appointed to the position of Chief Executive Officer of ProMetic BioSciences Ltd in February 2006 having served with the company since its formation. Dr Burton has over 23 years of commercial bioprocess and company management experience.
Dr Burton gained his Ph.D. at the University of Cambridge, UK researching novel affinity ligands for use in protein purification. After spending 2 years as a Research Scientist with Delta Biotechnology Ltd (now Novozymes) Dr Burton joined a new start-up company Affinity Chromatography Ltd as Research Manager and, following the establishment of a successful R&D group which developed Mimetic Ligand™ adsorbents and won the Queens Award for Technological Achievement, he was appointed R&D Director.
Following the acquisition in 1999 of Affinity Chromatography Ltd by ProMetic Life Sciences Inc., Dr Burton has held a variety of positions within the company and has established numerous commercial collaborations with medical and biopharmaceutical companies.
Download Slides
Please login to download the slides
Key Learning Objectives
- The advantages of adopting Affinity Chromatography as an initial capture step in downstream processes.
- The disadvantages of biological ligands
- The use of computational chemistry to understand protein-ligand interactions and to define potential affinity ligand structures.
- The use of automated screening methods to identify suitable affinity ligands and the optimization of subsequent chromatography conditions.
Audience
- Process Development
- Chromatography
- Protein Separations
- Affinity Chromatography
- Scale up
- Tech Transfer
- Large Scales Chromatography
- Downstream Processing
- Development Scientists
- Protein Chemist
- Department Head
